# Efficacy and Safety of Specific Immunotherapy With CLUSTOID Grass Pollen

> **NCT01012531** · PHASE3 · COMPLETED · sponsor: **Roxall Medizin** · enrollment: 121 (actual)

## Conditions studied

- Allergic Rhinitis

## Interventions

- **BIOLOGICAL:** Subcutaneous injections with highly polymerized allergen extract
- **BIOLOGICAL:** Subcutaneous injection with placebo

## Key facts

- **NCT ID:** NCT01012531
- **Lead sponsor:** Roxall Medizin
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-11
- **Final completion:** 2009-12
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2011-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01012531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01012531, "Efficacy and Safety of Specific Immunotherapy With CLUSTOID Grass Pollen". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01012531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*